Regulated Pricing Decisions and Diagnostic Test Choices in Personalized Medicine: Navigating the Implications Within Legal Frameworks
Zibin Cui,Xiangdong Liu,Zehua Feng,Zhengzong Huang
DOI: https://doi.org/10.2147/rmhp.s475929
2024-11-10
Risk Management and Healthcare Policy
Abstract:Zibin Cui, 1, &ast Xiangdong Liu, 2, &ast Zehua Feng, 3 Zhengzong Huang 4 1 School of Management, Guangdong University of Technology, Guangzhou, People's Republic of China; 2 Faculty of Humanities and Social Sciences, Macao Polytechnic University, Macao, People's Republic of China; 3 School of Law, Guangdong University of Technology, Guangzhou, People's Republic of China; 4 College of Humanities and Social Science, Shenzhen Technology University, Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zehua Feng; Zhengzong Huang, Email ; Background: The emerging risk of personalized medicine is driving drug manufacturers to seek collaborations with advanced diagnostic firms, aiming to improve detection and treatment outcomes. However, the government's regulated pricing in personalized medicine affects manufacturers' strategic decisions, particularly regarding the selection of diagnostic partners. In this context, this study investigates whether the government should regulate the price of personalized medicine and how the government's regulated pricing decisions affect drug manufacturers' diagnostic test choices. Methods: A stylized analytical model was developed, employing game-theoretic analysis. Numerical studies are also conducted to validate our results. Results: The study reveals that in the absence of the government's regulated pricing, drug manufacturers benefit from partnering with high-level diagnostic firms, enhancing consumer surplus and social welfare. However, when the government regulates pricing, the choice of partnering with a high-level diagnostic firm depends on specific conditions, such as low patient sensitivity to treatment failure and a low unit cost coefficient of diagnostic effort. The government's decision to regulate prices is influenced by three key parameters: patients' sensitivity to treatment failure, the unit cost coefficient of the diagnostic test effort, and the proportion of the price of specialized drugs in the regulated pricing. Conclusions: The findings underscore the importance of legal frameworks in the personalized medicine industry. The absence of the government's regulated pricing incentivizes collaborations with high-level diagnostic firms, enhancing consumer surplus and social welfare. However, government intervention in pricing makes such decisions contingent on specific conditions, requiring nuanced regulatory policies that balance the interests of patients, manufacturers, and diagnostic firms. Keywords: personalized medicine, partnership, government, regulated pricing, game theory The evolution of medical treatment has witnessed a significant shift from traditional methods to the more tailored approach of personalized medicine. Traditional medicine, while beneficial, often employs a "one-size-fits-all" approach, particularly evident in the treatment of diseases like lung cancer. 1 Unfortunately, this methodology does not account for individual genetic differences, leading to ineffective treatment for a significant proportion of patients. For instance, only about a quarter of cancer patients respond to these generic treatments due to the lack of consideration for their unique genetic makeup. 2,3 The advent of personalized medicine, heralded by the decoding of the human genome, has revolutionized this landscape. This approach leverages a patient's genetic profile to categorize them into specific subpopulations, thereby guiding more precise medical practices, drug selections, dosages, and timing. Such customization ensures that patients receive drugs that are highly effective for their specific condition. 4,5 As a result, personalized medicine has demonstrated significant advantages over traditional methods, notably in enhancing patient survival rates and improving the overall quality of life. 6 Furthermore, personalized medicine has been shown to be more effective and efficient than traditional medicine. In 2018, personalized medicine accounted for 42% of all new drugs approved by the US Food and Drug Administration (FDA), indicating its rapidly growing importance in healthcare. 7,8 Also, recent statistics indicate that the global personalized medicine market was valued at USD 529.28 billion in 2023 and is projected to grow at a CAGR of 8.20% from 2024 to 2030. Unlike the traditional approach, which often relies on non-personalized "blockbuster" drugs designed for the average patient, personalized medicine is based on diagnosing specific biomarkers to predict an individual's reaction to a particular drug. This method not only increases efficiency but also reduce -Abstract Truncated-
health care sciences & services,health policy & services